Patents by Inventor Carlos Estenio Hormaeche

Carlos Estenio Hormaeche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6680182
    Abstract: The invention provides a DNA molecule comprising a promoter sequence operably linked to a DNA sequence encoding first and second proteins linked by a hinge region wherein in that the promoter sequence can be one having activity which is induced in response to a change in the surrounding environment and the first protein can be Tetanus toxin C fragment or one or more epitopes thereof. The invention also provides intermediate molecules having a promoter operably linked to a DNA sequence encoding a first antigenic sequence and a hinge region, and at or adjacent the 3′-end thereof one or more restriction sites for the introduction of a second anti-genic sequence. In addition, the invention provides replicable expression vectors containing the DNA fusion proteins expressed therefrom, bacterial transformed with the vectors and the use of the bacteria, in vaccines.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: January 20, 2004
    Assignee: Acambis Research Limited
    Inventors: Mohammed Anjam Khan, Bernardo Villarreal-Ramos, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
  • Patent number: 6488926
    Abstract: The invention provides a DNA construct comprising a DNA sequence encoding a fusion protein of the formula: TetC-(Z)a-Het, wherein: TetC is the C fragment of tetanus toxin, or a protein comprising the epitopes thereof; Het is a heterologous protein, Z is an amino acid, and a is zero or a positive integer, provided that (Z)a does not include the sequence Gly-Pro. The invention also provides replicable expression vectors containing the constructs, bacteria transformed with the constructs, the fusion proteins per se and vaccine compositions formed from the fusion proteins or attenuated bacteria expressing the fusion proteins.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: December 3, 2002
    Assignee: Medeva Holdings B.V.
    Inventors: Mohammed Anjam Khan, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
  • Patent number: 6162433
    Abstract: The invention relates to DNA constructs encoding a safe, selectable marker, other than an antibiotic resistance marker, vectors and/or cells including said constructs; and vaccines based on said constructs for use in animals and particularly humans. The safe, selectable marker being a marker that confers resistance to an agent, other than an antibiotic, which would otherwise deleteriously affect the growth of a cell in which said construct was placed.
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: December 19, 2000
    Assignee: Medeva Europe Limited
    Inventors: Mohammed Anjam Khan, Hesta Varey McNeill, Carlos Estenio Hormaeche
  • Patent number: 5980907
    Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 9, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield
  • Patent number: 5811105
    Abstract: An attenuated microorganism harboring two mutated genes, each of which is located in the organisms aromatic pathway is provided. These organisms can usefully form the basis of a vaccine. They can be genetically engineered so as to express antigens from other pathogens and thus form the basis of a range of multi-valent vaccines.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: September 22, 1998
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Gordon Dougan, Steven Neville Chatfield, Carlos Estenio Hormaeche
  • Patent number: 5804194
    Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: September 8, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield
  • Patent number: 5770214
    Abstract: An attenuated microorganism harbouring two mutated genes, each of which is located in the organisms aromatic pathway is provided. These organisms can usefully form the basis of a vaccine. They can be genetically engineered so as to express antigens from other pathogens and thus form the basis of a range of multi-valent vaccines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Gordon Dougan, Steven Neville Chatfield, Carlos Estenio Hormaeche